- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07566845
Women With Previous GDM and the Effects of HIIT. (GDM-HIIT)
Deep Metabolic and Molecular Phenotyping of Women With Previous Gestational Diabetes Mellitus and the Responses to High-intensity Interval Training.
The goal of this clinical trial is to investigate if women with previous gestational diabetes (pGDM) are characterized with unique metabolic and molecular alterations compared to women without pGDM. Furthermore if 8 weeks of high-intensity interval training (HIIT) can improve these alterations. The main questions we aim to answer are:
- Women with pGDM have metabolic abnormalities compared with women without pGDM, and that these metabolic abnormalities are explained by unique molecular abnormalities in skeletal muscle and adipose tissue.
- Eight weeks of HIIT combining rowing and cycling can markedly improve these metabolic abnormalities in women with pGDM and these improvements are explained by beneficial cellular and molecular changes in skeletal muscle and adipose tissue.
Researchers will compare 20 women with pGDM to 20 glucosetolerant without pGDM, who are matched on age, BMI and times since last pregnancy.
Participants will undergo a screening visit and examinations on two separate days before (day 1 and day 2) and two separate days after (day 3 and day 4) 8-weeks of HIIT, in all cases after an overnight fast (≥ 12 h). Day 1 and day 3 will include assessment of body composition and VO2max. On day 2 and day 4, the insulin sensitivity, substrate metabolism, and β-cell function of the participants will be examined by a Botnia-clamp combined by indirect calorimetry. Skeletal muscle biopsies from m. vastus lateralis and subcutaneous abdominal adipose tissue biopsies are taken in the basal and insulin-stimulated states of each clamp.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Region Syddanmark
-
Odense, Region Syddanmark, 덴마크, 5000
- Steno Diabetes Center Odense, Odense University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age 25-45 years
- BMI 20-35 kg/m2
- 2-8 years since the last pregnancy
- No known diabetes or PCOS
- No previous bariatric surgery
- No known disease
- Be drug-naive
- Have a regular menstrual cycle (23-35 days)
- Not be pregnant or planning pregnancy during the study period
- Low or moderate level of physical activity must be (max 2 hours of moderate exercise weekly).
- All participants should be able to provide informed consent
- Women without pGDM must not have known hypertension or first-degree relatives with diabetes.
Exclusion Criteria:
- Abnormal cardiac stethoscopy, ECG or screening blood tests
- Positive plasma GAD-65 antibodies
- Positive plasma choriogonadotropine
- Undiagnosed T2D based on fasting plasma glucose (≥ 7.0 mmol/mol), plasma HbA1c (≥ 48 mmol/mol), or 2-h plasma glucose during an oral glucose tolerance test (OGTT) (≥ 11.1 mmol/mol)
- Dyslipidemia (plasma LDL-cholesterol > 5.0 mmol/l)
- In women with pGDM: Undiagnosed severe hypertension (blood pressure > 160/100)
- In women without pGDM: Undiagnosed hypertension (blood pressure >140/90 mmHg) or impaired glucose tolerance (fasting plasma glucose at 6.16.9 mmol/l, plasma HbA1c at 42-47 mmol/mol, or a 2-h glucose at 7.8-11.0 mmol/l during an OGTT).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Women with previous gestational diabetes mellitus
Women with previous gestational diabetes mellitus, aged 25-45, who gave birth 2-8 years ago.
|
The training intervention consists of 8-weeks of HIIT combining rowing and cycling on ergometers with two supervised sessions weekly in small groups of up to 10 participants.
All HIIT sessions will start with a 10-min warm-up period followed by training blocks of 5 x 1 min high-intensity intervals (100-110% of Wattmax corresponding to ≥ 85% of maximum heart rate (HRmax)) each interspersed by 1 min active or resting recovery.
Between the training blocks, the participants will have a 4-min break in which they shift from cycling to rowing or vice versa.
The number of training blocks will gradually increase from two to five blocks during the 8-week intervention period with one block being added every second week.
Halfway through the HIIT-protocol the workload will be adjusted according to a midway VO2max test.
Participants will wear a heart monitor during training sessions.
|
|
활성 비교기: Women without previous gestational diabetes
Women without previous gestational diabetes mellitus, aged 25-45, who gave birth 2-8 years ago.
|
The training intervention consists of 8-weeks of HIIT combining rowing and cycling on ergometers with two supervised sessions weekly in small groups of up to 10 participants.
All HIIT sessions will start with a 10-min warm-up period followed by training blocks of 5 x 1 min high-intensity intervals (100-110% of Wattmax corresponding to ≥ 85% of maximum heart rate (HRmax)) each interspersed by 1 min active or resting recovery.
Between the training blocks, the participants will have a 4-min break in which they shift from cycling to rowing or vice versa.
The number of training blocks will gradually increase from two to five blocks during the 8-week intervention period with one block being added every second week.
Halfway through the HIIT-protocol the workload will be adjusted according to a midway VO2max test.
Participants will wear a heart monitor during training sessions.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
β-cell function by OGTT
기간: At screening visit.
|
Will be estimated as the disposition index (DI) by oral glucose tolerance test (OGTT) derived indices of insulin sensitivity and insulin secretion, after a 2-hour OGTT (75g) with measurement of plasma glucose, serum insulin and serum C-peptide at 0, 30 and 120 min.
|
At screening visit.
|
|
β-cell function by Botnia-clamp
기간: At examination day 2 and 4.
|
β-cell function adjusted for insulin sensitivity will be determined by calculating the DI as a product of the acute insulin response to glucose (AIRg) and insulin-stimulated glucose infusion rate (GIR).
|
At examination day 2 and 4.
|
|
Whole body composition (lean body mass and fat mass)
기간: At examination day 1 and 3.
|
Will be obtained by a dual-energy X-ray absorptiometry (DXA) scanning (Prodigy Advance, GE Healthcare, CHI, US)
|
At examination day 1 and 3.
|
|
Lean body mass
기간: At examination day 1 and 3.
|
Will be obtained by a dual-energy X-ray absorptiometry (DXA) scanning (Prodigy Advance, GE Healthcare, CHI, US)
|
At examination day 1 and 3.
|
|
Fat mass
기간: At examination day 1 and 3.
|
Will be obtained by a dual-energy X-ray absorptiometry (DXA) scanning (Prodigy Advance, GE Healthcare, CHI, US)
|
At examination day 1 and 3.
|
|
Cardiorespiratory fitness (maximal oxygen consumptions (VO2-max))
기간: At examination day 1 and 3.
|
Will be determined by an incremental exercise test on a cycle ergometer (SRM Ergometer System, Jülich, DE) combined with mixed chamber cardiopulmonary exercise analyzer (Oxigraf, Model O2CPX, California, US)
|
At examination day 1 and 3.
|
|
Insulin sensitivity by Botnia-clamp
기간: At examination day 2 and 4.
|
Consisting of a hyperinsulinemic-euglycemic clamp (insulin 40mU/min/m2 for 3 h) combined with a 60 min intravenous glucose tolerance test (IVGGT) using a glucose bolus (0.3 kg per kg body weight with a maximum of 25 g glucose).
|
At examination day 2 and 4.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Plasma-specific metabolomics by LC- and GC-MS
기간: At examination day 2 and 4.
|
Liquid chromatography (LC)- and gas chromatography (GS)-based mass spectrometry (MS) will be used to detection, identification, and quantitation of very large numbers of metabolites in the micro- and nano-molar range in body fluids, such as blood.
|
At examination day 2 and 4.
|
|
Tissue-specific metabolomics by LC- and GC-MS
기간: At examination day 2 and 4.
|
Liquid chromatography (LC)- and gas chromatography (GS)-based mass spectrometry (MS) will be used to detection, identification, and quantitation of very large numbers of metabolites in the micro- and nano-molar range in body tissues.
|
At examination day 2 and 4.
|
|
Proteomics
기간: At examination day 2 and 4.
|
To identify biological processes and signaling networks altered in women with pGDM and changed in response to HIIT, we will apply unbiased mass-spectrometry based proteome analysis of the skeletal muscle and adipose tissue biopsies.
|
At examination day 2 and 4.
|
|
Phosphoproteomics
기간: At examination day 2 and 4.
|
To identify biological processes and signaling networks altered in women with pGDM and changed in response to HIIT, we will apply unbiased mass-spectrometry based phosphoproteome analysis of the skeletal muscle and adipose tissue biopsies.
|
At examination day 2 and 4.
|
|
Transcriptional profiling and gene expression
기간: At examination day 2 and 4.
|
High-resolution transcriptional profiling of abdominal adipose tissue and skeletal muscle biopsies will be performed using total RNA sequencing with next generation sequencing (TruSeq® Stranded Total RNA Library Prep Gold; Illumina). Gene expressions are quantified using Targeted quantitative real-time PCR (qRT-PCR) and Western Blotting. |
At examination day 2 and 4.
|
|
Mitochondrial respiration
기간: At examination day 2 and 4.
|
Will be measured on permeabilized muscle fibers, and analyzed by measuring oxygen consumption when adding substrates, uncouplers, and inhibitors to the chambers of a high-resolution oxygraphy.
|
At examination day 2 and 4.
|
|
Lipid droplets by TEM
기간: At examination day 2 and 4.
|
The morphology, volume, and localization of lipid droplets in muscle biopsies from the study cohorts will be determined by Transmission Electron Microscopy (TEM).
|
At examination day 2 and 4.
|
|
Mitochondria by TEM
기간: At examination day 2 and 4.
|
The morphology, volume, and localization of mitochondria in muscle biopsies from the study cohorts will be determined by Transmission Electron Microscopy (TEM).
|
At examination day 2 and 4.
|
|
Lipid droplet interaction with mitochondria by TEM
기간: At examination day 2 and 4.
|
The the physical interaction between lipid droplets and mitochondria in muscle biopsies from the study cohorts will be determined by Transmission Electron Microscopy (TEM).
|
At examination day 2 and 4.
|
|
Protein abundance
기간: At examination day 2 and 4.
|
Protein abundance will be studied in skeletal muscle and adipose tissue biopsies by Western blotting procedures.
|
At examination day 2 and 4.
|
|
Phosphorylation of enzymes
기간: At examination day 2 and 4.
|
Phosphorylation of enzymes will be studied in skeletal muscle and adipose tissue biopsies by Western blotting procedures.
|
At examination day 2 and 4.
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lipid profile
기간: At examination day 2 and 4.
|
Plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, non-HDL-cholesterol and triglycerides determined by blood tests.
|
At examination day 2 and 4.
|
|
HbA1c
기간: At examination day 2 and 4.
|
Determined by blood tests.
|
At examination day 2 and 4.
|
|
Insulin
기간: At examination day 2 and 4.
|
Determined by blood tests.
|
At examination day 2 and 4.
|
|
Glucose
기간: At examination day 2 and 4.
|
Determined by blood tests.
|
At examination day 2 and 4.
|
|
C-peptide
기간: At examination day 2 and 4.
|
Determined by blood tests.
|
At examination day 2 and 4.
|
|
Levels of systemic low-grade inflammation
기간: At examination day 2 and 4.
|
Circulating levels of adiponectin, leptin, interleukin-6 (IL-6), fibroblast growth factor 21 (FGF21), angiopoietin-like 4 (ANGPTL4) and growth differentiation factor 15 (GDF15) will be measured in bloodsamples.
|
At examination day 2 and 4.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Kurt Højlund, Prof. Dr. med., Steno Diabetes Center Odense, Odense University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 25/55674
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제2형 당뇨병(T2DM)에 대한 임상 시험
-
Embecta Corp.Jaeb Center for Health Research빼는제2형 당뇨병 | 제2형 당뇨병(T2DM) | T2DM(제2형 당뇨병) | T2D | T2DM | 유형 2 DM | 혈당 조절이 부적절한 T2DM미국
-
University of North Carolina, Chapel HillAmerican Heart Association모병제2형 당뇨병 | 영양물 섭취 | 당뇨병 유형 2 | T2DM(제2형 당뇨병) | 당뇨병 진성염 | T2DM | 당뇨병 교육미국
-
Postgraduate Institute of Medical Education and...완전한
-
University Hospital, GhentUniversity Ghent; Universiteit Antwerpen; University of Parma모병
-
University of North Carolina, Chapel HillAmerican Diabetes Association아직 모집하지 않음제2형 당뇨병(T2DM) | 당뇨병(DM) | 인슐린 의존성 당뇨병 | 1형 당뇨병(T1D) | 당뇨병 교육 | 당뇨병 관리 | 당뇨병 (인슐린 수용, 1 형 또는 유형 2)미국
-
Amgen모집하지 않고 적극적으로제 2 형 당뇨병 (T2DM), 비만, 과체중캐나다, 미국, 헝가리, 영국, 독일, 이탈리아, 체코, 푸에르토 리코, 일본, 불가리아, 폴란드, 대한민국, 아르헨티나
-
Hangzhou SynRx Therapeutics Biomedical Technology...모병유방암 | 난소 암 | 고급 고형 종양 | 전이성 고형 종양 | BRCA 1/2 및/또는 HRD중국
-
Duke UniversityEli Lilly and Company; Bayer; Boehringer Ingelheim모병제2형 당뇨병(T2DM) | 만성신장질환(CKD) | 유형 2 DM미국
-
Duke UniversityEli Lilly and Company; Bayer; Boehringer Ingelheim모병제2형 당뇨병(T2DM) | 만성신장질환(CKD) | 유형 2 DM미국
-
Truway Health, Inc.초대로 등록고혈압 | 대사 증후군 | 만성 질환 | 말초 동맥 질환 | 고지혈증 | 당뇨병 전단계 | 심혈관 질환 급성 | 제 2 형 당뇨병 (T2DM), 비만, 과체중 | 만성 신장 질환 (CKD), 3-4 단계 운동 내성 / 기능 용량 혈관 건강 / 동맥 강성 피로미국
High-intensity interval training에 대한 임상 시험
-
Seattle Children's HospitalLouisiana State University Health Sciences Center in New Orleans완전한
-
Rhode Island HospitalUniversity of Puerto Rico모병